<DOC>
	<DOCNO>NCT00350987</DOCNO>
	<brief_summary>The aim study test procalcitonin ( PCT ) guide antibiotic stewardship patient low respiratory tract infection ( LRTI ) non-inferior , bad 7.5 % high combined failure rate , compare standard care practice ( current guideline LRTI ) reduce total antibiotic ( AB ) use hospitalization rate duration , respectively .</brief_summary>
	<brief_title>Procalcitonin Guided Antibiotic Therapy Hospitalisation Patients With Lower Respiratory Tract Infections : The `` ProHOSP '' Study</brief_title>
	<detailed_description>Background : Acute low respiratory tract infection ( LRTI ) , i.e . acute bronchitis acute exacerbation chronic obstructive pulmonary disease ( AECOPD ) , community-acquired pneumonia ( CAP ) , employ important hospital resource often unnecessary antibiotic ( AB ) treatment course . We demonstrate four intervention trial enrol &gt; 1200 patient procalcitonin ( PCT ) -guidance markedly reduce AB prescription duration . To ascertain external validity , safety potential improve allocation health care resource , non-inferiority multicenter intervention trial do . Aim : To compare strategy base evidence-based guideline PCT guide AB therapy LRTI respect outcome ( combine disease-specific failure rate ) , use AB hospital resource . Design : Investigator-initiated , controlled trial open intervention . Patients admit LRTI hospital include randomized 1:1 either standard management PCT-guided prescription AB . Randomization stratify centre ( hospital ) type LRTI ( Acute bronchitis/AECOPD/CAP ) . Setting : Teaching hospital tertiary care clinic northwestern central Switzerland . Patients : 18 year old , LRTI &gt; 1 &lt; 28 day duration . Excluded patient without informed consent , fluent German , unlikely comply , severe immuno-suppression , terminal condition death expect occur current hospitalization , immediate need intensive care . Endpoints : - Primary : Risk combine disease-specific failure 30 day . - Secondary : AB exposure , side effect ABs , time AB treatment , rate duration hospitalization , time clinical stability , disease activity score . Endpoints assess baseline , daily hospitalize patient 30 180 day structure phone interview blind medical student . Intervention : Participating physician receive evidence-based guideline management patient LRTIs . Patients LRTI randomize PCT plus guideline ( `` PCT group '' ) versus guidelines-guided AB treatment ( `` control group '' ) . In patient randomized PCT group use ABs le discourage ( &lt; 0.1 &lt; 0.25 ug/L ) encourage ( &gt; 0.5 &gt; 0.25 ug/L ) , respectively . A re-evaluation 6 24 hour patient antibiotic withhold worsen non-improvement vital sign PCT ( &lt; 0.1 &lt; 0.25 ug/L ) recommend . During hospitalization , patient AB treatment reassess day 3 , 5 7 patient randomized PCT group recommend stop AB base PCT level . In AB-treated outpatient discharge patient AECOPD CAP randomize PCT group uncomplicated course , recommend duration AB therapy base last PCT level follow : &gt; 0.5 ug/L , 5 day ; &gt; 0.25 ug/L , 3 day ; &lt; 0.25 ug/L , stop AB . Variables measurement : Centers consecutively enroll patient LRTI . Baseline data medical history clinical item , additional diagnostic test , co-morbidity , final prescribed treatment reason hospital admission stay collect . After pilot/feasibility phase 3 month , study recruitment continue Mar 2007 Apr 2008 . Study hypothesis : PCT guidance non-inferior worst 7.5 % high combined failure rate compare standard care practice reduce total AB use hospitalization rate duration , respectively . Analyses : These do base intention-to-treat per-protocol principle . With assumed combined failure rate 15 % 20 % , non-inferiority margin 7.5 % , maximum 5 % loss follow-up , value 5 % power 90 % , total sample size 806 α one-sided 1002 . Interim monitoring : Regular review serious adverse event , quality integrity study independent data safety monitor board . Safety interim analysis blind assessment ( i.e. , arm pool ) diagnostic prognostic accuracy biomarkers 50 % patient recruit . Ancillary project : Six related project perform alongside study ( include , cost-effectiveness , nurse social influence hospitalization , prognostic value novel biomarkers ) synergize scientific effort . Significance : Due high prevalence absorption hospital resource , study offer potential large improvement management LRTIs , along substantial reduction hospitalization cost AB resistance .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<criteria>1 . Patients 18 year age old , admit community nursing home acute ( i.e. , least 1 day less 28 day ) LRTI main diagnosis consist least two follow : new increased respiratory sign symptom ( i.e. , cough , sputum production , dyspnea , auscultatory finding abnormal breath sound rale , pleuritic chest pain ) without inflammatory sign ( core body temperature &gt; 38.0° C , leukocyte count &gt; 10 &lt; 4 x 10^9 cell L1 ) . CAP define presence LRTI along new increase infiltrate chest radiograph . Severity score CAP ( pneumonia severity index [ PSI ] CURB65 ) calculate . COPD define postbronchodilator spirometric criterion accord GOLDguidelines FEV1/FVC ratio 70 % severity categorize mild ( FEV1 &lt; = 80 % predict ) , moderate ( 50 % &gt; = FEV1 &lt; 80 % ) , severe ( 30 % &gt; = FEV1 &lt; 50 % ) severe ( FEV1 &lt; 30 % ) , respectively . Severity acute exacerbation COPD grade propose . Acute bronchitis define LRTI absence underlie lung disease focal chest sign infiltrate chest Xray , respectively . Patients admission judge LRTI another final diagnosis , classify `` others '' . 2 . Ability understand verbal write instruction inform consent . 1 . Patients unable give write informed consent , e.g . severe dementia patient understanding German ( local language ) translation ( e.g . family member ) available . 2 . Patients active intravenous drug use . 3 . Severe immunosuppression ( e.g . patient infected human immunodeficiency virus infection CD4 count 350 x 10^9/L , patient immunosuppressive therapy solid organ transplantation neutropenic patient present neutrophil count &lt; 500 x 10^9/L patient chemotherapy neutrophils 5001000 x 10^9/L expect decrease value &lt; 500 x 10^9/L ) ; patient cystic fibrosis , infection M. tuberculosis , L. pneumophila , Listeria spp . hospital stay within 14 day inclusion . 4 . Accompanying chronic ( e.g . osteomyelitis ) , abscess ( e.g . brain , pleural empyema ) infection endocarditis . 5 . Terminal severe medical comorbidity death imminent expect current hospitalization ( e.g . due malignancy , cardiac , renal hepatic failure , comfort therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Procalcitonin , guideline , LRTI , non-inferiority</keyword>
	<keyword>COLD</keyword>
</DOC>